PMCCPMCCPMCC

Aide
Les critères de recherche 

Avancée
Logo of bttDove Medical PressSubscribeSubmit a ManuscriptSearchFollowDovepressBiologics: Targets and Therapy
 
Volume 7;  2013
Original Research
Duration of remission after halving of the etanercept dose in patients with ankylosing spondylitis: a randomized, prospective, long-term, follow-up study
Fabrizio Cantini, Laura Niccoli, Emanuele Cassarà, Olga Kaloudi, Carlotta Nannini
Biologics. 2013; 7: 1–6. Published online 2013 January 4. doi: 10.2147/BTT.S31474
PMCID:
PMC3540908
Résumé Texte intégral PDF–203K
Factors correlated with improvement of endothelial dysfunction during rituximab therapy in patients with rheumatoid arthritis
Maurizio Benucci, Gianantonio Saviola, Mariangela Manfredi, Piercarlo Sarzi-Puttini, Fabiola Atzeni
Biologics. 2013; 7: 69–75. Published online 2013 March 15. doi: 10.2147/BTT.S39182
PMCID:
PMC3603333
Résumé Texte intégral PDF–220K
Reviews
Profile of reslizumab in eosinophilic disease and its potential in the treatment of poorly controlled eosinophilic asthma
Garry M Walsh
Biologics. 2013; 7: 7–11. Published online 2013 January 9. doi: 10.2147/BTT.S30133
PMCID:
PMC3544267
Résumé Texte intégral PDF–143K
Relapsed and refractory lymphoid neoplasms and multiple myeloma with a focus on carfilzomib
Ajay Nooka, Charise Gleason, Daniela Casbourne, Sagar Lonial
Biologics. 2013; 7: 13–32. Published online 2013 January 30. doi: 10.2147/BTT.S24580
PMCID:
PMC3563316
Résumé Texte intégral PDF–506K
Treatment of hemophilia B: focus on recombinant factor IX
Massimo Franchini, Francesco Frattini, Silvia Crestani, Cinzia Sissa, Carlo Bonfanti
Biologics. 2013; 7: 33–38. Published online 2013 February 12. doi: 10.2147/BTT.S31582
PMCID:
PMC3575125
Résumé Texte intégral PDF–446K
Critical appraisal of axitinib in the treatment of advanced renal cell carcinoma
Jawaher Ansari, Syed A Hussain, Asif Ansari, John Glaholm
Biologics. 2013; 7: 39–46. Published online 2013 February 28. doi: 10.2147/BTT.S25862
PMCID:
PMC3588609
Résumé Texte intégral PDF–247K
Histone deacetylase inhibitors (HDACIs): multitargeted anticancer agents
Katherine Ververis, Alison Hiong, Tom C Karagiannis, Paul V Licciardi
Biologics. 2013; 7: 47–60. Published online 2013 February 25. doi: 10.2147/BTT.S29965
PMCID:
PMC3584656
Résumé Texte intégral PDF–790K
Focus on the potential role of ficlatuzumab in the treatment of non-small cell lung cancer
Manolo D’Arcangelo, Federico Cappuzzo
Biologics. 2013; 7: 61–68. Published online 2013 March 3. doi: 10.2147/BTT.S28908
PMCID:
PMC3593708
Résumé Texte intégral PDF–247K
Clinical use of crizotinib for the treatment of non-small cell lung cancer
Patrick J Roberts
Biologics. 2013; 7: 91–101. Published online 2013 April 26. doi: 10.2147/BTT.S29026
PMCID:
PMC3643289
Résumé Texte intégral PDF–971K
Hereditary angioedema: epidemiology, management, and role of icatibant
Aasia Ghazi, J Andrew Grant
Biologics. 2013; 7: 103–113. Published online 2013 May 3. doi: 10.2147/BTT.S27566
PMCID:
PMC3647445
Résumé Texte intégral PDF–276K
Bosutinib in the management of chronic myelogenous leukemia
Gunhild Keller-von Amsberg, Philippe Schafhausen
Biologics. 2013; 7: 115–122. Published online 2013 May 6. doi: 10.2147/BTT.S30182
PMCID:
PMC3652479
Résumé Texte intégral PDF–221K
Les articles de Biologics : Targets & Therapy ont été offerts à titre gracieux par
Dove Press.